News | July 11, 2023
Sumitomo Pharma America launches as new combined organization
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Advances clinical research capabilities with leading regulatory grade registries platform
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
_256_384.jpg)
The collaboration aims to raise awareness about eye cancer, provide medical and surgical treatment support to children and supply nutritional supplements to aid in their faster recovery.
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
The company has received Export Performance Award - API & Intermediaries Gold Star for the year 2021-22
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Subscribe To Our Newsletter & Stay Updated
